Core Viewpoint - The ongoing dispute between Aikang Guobin and lawyer Zhang Xiaoling centers around allegations of misdiagnosis and the integrity of health check reports, with both parties engaging in legal actions against each other [1][3][4]. Group 1: Dispute Details - Zhang Xiaoling was diagnosed with late-stage kidney cancer after ten years of health check reports from Aikang Guobin showing "no abnormalities," leading her to question the validity of the checks [1]. - Aikang Guobin has denied any wrongdoing, asserting that there were no misdiagnoses or false health checks, and has initiated legal proceedings against Zhang Xiaoling [1][2]. - The dispute has escalated, with both parties filing lawsuits against each other, indicating a significant conflict [1][3]. Group 2: Medical Reports and Responses - During a media briefing, Aikang Guobin presented parts of Zhang Xiaoling's 2023 health check report, which indicated potential kidney issues and recommended further examinations [2]. - Aikang Guobin clarified that blood samples are typically only preserved for 1-7 days, making it impossible to retain samples from the past ten years [2]. - Zhang Xiaoling has requested the disclosure of her health check data and related information, while Aikang Guobin stated that such disclosure requires her written authorization [3]. Group 3: Industry Context - The health check service market in China has seen a compound annual growth rate of 11.1% from 2016 to 2020, with projections estimating the market size to reach 394.3 billion yuan by 2025 [5]. - Aikang Group operates multiple brands, providing a range of health management services across 170 centers in 54 cities as of May 2025 [5]. - The founder of Aikang Group has previously highlighted issues within the health check industry, emphasizing the distinction between health checks and medical consultations [6][7].

Core Viewpoint - Despite the founder's efforts to expose industry malpractices and the company's commitment to quality and customer-centric values, iKang Guobin continues to face various issues and scandals in the health examination sector [2][16]. Group 1: Company Background and Development - iKang Guobin, once known as "China's health examination first stock," was founded by Zhang Ligang, who leveraged his internet background to understand user operations and capital management, leading to a successful IPO within ten years of establishment [5]. - The company went public on NASDAQ on April 9, 2014, with an initial closing price of $15.2 per ADS, an increase of 8.57% from the offering price of $14 [7]. - However, due to a general downturn for Chinese stocks in overseas markets, iKang Guobin's stock price stagnated between $10 and $20 per ADS for several years, prompting the company to initiate privatization in August 2015 at a price of $17.8 per ADS [8][9]. Group 2: Financial Performance and Market Position - In the fiscal year 2014, iKang Guobin reported revenues of $290 million, a year-on-year increase of 43.7%, with a Non-GAAP net profit of $36.3 million, up 60.9% [10]. - In contrast, its competitor, Meinian Health, reported revenues of 6.233 billion yuan and a net profit of 614 million yuan in 2017, significantly lower than iKang Guobin's figures at that time [10]. - As of November 2024, iKang Guobin operates 173 health examination centers across 57 cities, showing limited growth with an average increase of only 10 centers per year since 2018 [12]. Group 3: Industry Challenges and Issues - The health examination industry in China has faced numerous scandals, including sample mix-ups and data errors, leading to a lack of standardized operations [16]. - Zhang Ligang publicly exposed these issues at the China Enterprise Leaders Annual Conference in December 2018, highlighting severe malpractice within the industry [16]. - Despite the company's stated values of quality and customer trust, iKang Guobin continues to encounter various operational problems, undermining its credibility [2][16].